Skip to main content
European Commission logo print header

Oral biopharmaceutics tools

Objective

The OrBiTo project will deliver novel methods and a framework for rational application of predictive biopharmaceutics tools for oral drug delivery. This will be achieved through novel propsective studies to define new methodlogies which will be validated using historical datasets from EFPIA partners. A combination of high quality in vitro or in silico characterizations of API and formulations will be integrated into physiologically based in silico models capturing the full complexity of oral drug absorption. This approach will drive model based pharmaceutical product development in accordance with visions of Quality by Design. Benefits include an accelerated formulation development process, particularly for challenging projects e.g. for low solubility molecules or modified-release formulations as well as allowing optimization of clinical product performance for patient benefit. In addition, it will significantly reduce the need for future animal experiments in this area and reduce the need for human bioequivalence studies for bridging between formulations within clinical programmes. The consortium is composed of world-leading scientists in a unique multidisciplinary collaboration where competences from nine academic partners, one regulatory agency, one non-profit research organisation and three SMEs are brought together with the twelve EFPIA partners giving an unparalleled opportunity to deliver transformational change in European industrial product development.

Call for proposal

IMI-JU-04-2011
See other projects for this call

Coordinator

ASTRAZENECA AB
EU contribution
No data
Address
Vastra Maelarhamnen
151 85 Sodertaelje
Sweden

See on map

Region
Östra Sverige Stockholm Stockholms län
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Principal investigator
Bertil Abrahamsson (Senior Principle Scientist)
Administrative Contact
Eva Lindgren (Senior Director)
Links
Total cost
No data

Participants (26)